Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
BMC Cardiovasc Disord ; 14: 169, 2014 Nov 25.
Artigo em Inglês | MEDLINE | ID: mdl-25425404

RESUMO

BACKGROUND: Glucose-insulin-potassium (GIK) has been advocated in the setting of acute coronary syndrome (ACS) to reduce ischemia-related arrhythmias and myocardial injury. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess whether the use of GIK infusions >3 or <3 hours after the onset of symptoms reduce mortality or cardiac arrest. METHODS: Electronic databases (Medline, EMBASE, and Cochrane Central Register of Controlled Trials) and references of retrieved articles were searched for RCTs evaluating the effect of GIK infusions, <3 hours or >3 hours after the onset of symptoms, on mortality and/or cardiac arrest. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for each outcome. RESULTS: Nine trials were identified and eligible for review. The summary OR for in-hospital mortality was 1.01 (95% CI 0.94 to 1.09), based on 2,542 deaths among 27,294 patients. The subgroup analysis according to the study enrollment time (within 3 hours [OR, 0.77, 95% CI 0.50-1.16], vs. >3 hours [OR, 0.90; 95% CI, 0.67-1.21]) did not reveal any difference in mortality. CONCLUSIONS: Administration of GIK in ACS patients does not significantly reduce mortality whether or not GIK administration >3 or <3 hours after the onset of symptoms.


Assuntos
Síndrome Coronariana Aguda/tratamento farmacológico , Soluções Cardioplégicas/administração & dosagem , Parada Cardíaca/prevenção & controle , Ensaios Clínicos Controlados Aleatórios como Assunto , Síndrome Coronariana Aguda/complicações , Síndrome Coronariana Aguda/mortalidade , Soluções Cardioplégicas/efeitos adversos , Distribuição de Qui-Quadrado , Esquema de Medicação , Glucose/administração & dosagem , Glucose/efeitos adversos , Parada Cardíaca/etiologia , Parada Cardíaca/mortalidade , Mortalidade Hospitalar , Humanos , Infusões Parenterais , Insulina/administração & dosagem , Insulina/efeitos adversos , Razão de Chances , Potássio/administração & dosagem , Potássio/efeitos adversos , Fatores de Risco , Fatores de Tempo , Tempo para o Tratamento , Resultado do Tratamento
2.
BMC Cell Biol ; 13: 23, 2012 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-22928917

RESUMO

BACKGROUND: Ovarian hyper stimulation syndrome (OHSS) is an iatrogenic complication associated with fertility drugs. It is characterized by increased vascular permeability and substantial fluid shift with accumulation in the body cavity. The pathogenesis of OHSS remains obscure, and no definitive treatments are currently available. RESULTS: Using western blot and short-circuit current (Isc) techniques, we investigate the potential coactions of analysis in cystic fibrosis transmembrane conductance regulator (CFTR) and aquaporin 1 (AQP1) on the hyper permeability of body cavity peritoneal epithelial cells in the pathogenesis of OHSS. The rats develop OHSS symptoms, with the up regulation of both CFTR and AQP1 expression and enhanced CFTR channel activity in peritoneal epithelial cells, can also be mimicked by administration of estrogen, alone in ovariectomized rats. Administration of progesterone suppresses CFTR activity, OHSS symptoms as well as CFTR and AQP1 expression. Besides, AQP1 inhibitor, HgCl(2), can suppress CFTR channel activity. Therefore, antisera against CFTR or AQP1 to OHSS animals may result in alleviation of the symptom. CONCLUSION: This study confirms the coactions of CFTR and AQP1 play a critical role in the development and progression of increased peritoneal epithelial permeability in severe OHSS. These findings may provide grounds for ameliorating assisted reproduction treatment strategy to reduce the risk of OHSS in in vitro fertilization (IVF).


Assuntos
Aquaporina 1/metabolismo , Regulador de Condutância Transmembrana em Fibrose Cística/metabolismo , Células Epiteliais/efeitos dos fármacos , Estrogênios/farmacologia , Síndrome de Hiperestimulação Ovariana/metabolismo , Animais , Aquaporina 1/antagonistas & inibidores , Permeabilidade da Membrana Celular/efeitos dos fármacos , Regulação para Baixo/efeitos dos fármacos , Células Epiteliais/metabolismo , Feminino , Cloreto de Mercúrio/farmacologia , Síndrome de Hiperestimulação Ovariana/etiologia , Progesterona/farmacologia , Ratos , Ratos Sprague-Dawley , Regulação para Cima/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA